Benelux GM1 Gangliosidosis Market Size & Outlook, 2026-2034
Benelux GM1 Gangliosidosis Market Insights
- As per Reed Intelligence insights, the Benelux GM1 Gangliosidosis Market stood at USD 2.34 Million in 2025 and is anticipated to grow to USD 9.06 Million by 2034.
- The Benelux market is expected to advance at a CAGR of 16.13% from 2026 through 2034.
- In 2025, Gene Therapy accounted for the highest share of the By Therapy Type market size.
- During the forecast period, Gene Therapy is set to register the highest growth, making it the most lucrative By Therapy Type segment.
![Benelux GM1 Gangliosidosis Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/benelux-gm1-gangliosidosis-market-benelux-by-therapy-type-119986.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Benelux represented 1.26% of the overall global GM1 Gangliosidosis Market size.
- United States is projected to lead the global GM1 Gangliosidosis Market size by 2034.
- Across Europe, Germany is anticipated to hold the dominant position in market size by 2034.
- United Kingdom is forecasted to expand at the fastest pace in Europe, attaining USD 36.19 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 2.34 Million |
| Market Size In 2034 | USD 9.06 Million |
| Largest segment | Gene Therapy |
| Units | Revenue in USD Million |
| CAGR | 16.13% (2026-2034) |
| Segmnetation Covered | |
| By Therapy Type |
|
| By Disease Type |
|
| By Treatment Modality |
|
| By End-Use |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Benelux GM1 Gangliosidosis Market By Therapy Type 2026-2034 (USD Million)
| By Therapy Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Therapy | XX.x | XX.x | XX.x | 1.23 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme Replacement Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Substrate Reduction Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Benelux GM1 Gangliosidosis Market By Disease Type 2026-2034 (USD Million)
| By Disease Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type 1 (Infantile) | XX.x | XX.x | XX.x | 1.22 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Type 2 (Juvenile) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Type 3 (Adult/Chronic) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Benelux GM1 Gangliosidosis Market By Treatment Modality 2026-2034 (USD Million)
| By Treatment Modality | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacological Treatment | XX.x | XX.x | XX.x | 1.29 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gene Editing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Supportive Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Benelux GM1 Gangliosidosis Market By End-Use 2026-2034 (USD Million)
| By End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 1.06 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Benelux GM1 Gangliosidosis Market By Distribution Channel 2026-2034 (USD Million)
| By Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 1.25 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.